RSEFX
Price
$17.05
Change
-$0.16 (-0.93%)
Updated
Jun 15 closing price
Net Assets
483.92M
SSGSX
Price
$52.76
Change
-$0.16 (-0.30%)
Updated
Jun 15 closing price
Net Assets
4.71B
Interact to see
Advertisement

RSEFX vs SSGSX

Header iconRSEFX vs SSGSX Comparison
Open Charts RSEFX vs SSGSXBanner chart's image
RSEFX vs SSGSX Comparison Chart in %
View a ticker or compare two or three
VS
RSEFX vs. SSGSX commentary
Jun 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSEFX is a Buy and SSGSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
SSGSX has more cash in the bank: 4.71B vs. RSEFX (484M). RSEFX pays higher dividends than SSGSX: RSEFX (1.66) vs SSGSX (0.54). RSEFX was incepted earlier than SSGSX: RSEFX (23 years) vs SSGSX (27 years). RSEFX (1.64) is less costly to investors than SSGSX (1.23). SSGSX is a more actively managed with annual turnover of: 50.00 vs. RSEFX (12.00). RSEFX has a lower initial minimum investment than SSGSX: RSEFX (2000) vs SSGSX (2500). SSGSX (25.22) and RSEFX (25.21) have marching annual gain over last year. SSGSX return over 5 years is better than : -3.94 vs. RSEFX (-13.64).
RSEFXSSGSXRSEFX / SSGSX
Total Expense Ratio1.491.23121%
Annual Report Gross Expense Ratio1.641.23133%
Fund Existence23 years27 years-
Gain YTD21.35218.416116%
Front LoadN/A6%-
Min. Initial Investment2000250080%
Min. Initial Investment IRAN/AN/A-
Net Assets484M4.71B10%
Annual Yield % from dividends1.660.54306%
Returns for 1 year25.2125.22100%
Returns for 3 years6.0714.5442%
Returns for 5 years-13.64-3.94346%
Returns for 10 years-1.2146.17-3%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHG69.752.45
+3.64%
Shinhan Financial Group Co Ltd
ABUS4.340.08
+1.76%
Arbutus Biopharma Corp
KNSA52.430.54
+1.04%
Kiniksa Pharmaceuticals International plc
PLX2.06-0.03
-1.44%
Protalix BioTherapeutics
TRAW0.75-0.53
-41.56%
Traws Pharma Inc